|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,040.50 DKK | +0.42% |
|
-0.29% | +36.48% |
| 01:33pm | Genmab announces data from multiple clinical trials | RE |
| 01:33pm | Genmab presents phase 3 data from EPCORE FL-1 trial | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 726Cr | 895.7Cr | 989.3Cr | 1.49TCr | 985.8Cr | |||||
Short Term Investments | 881.9Cr | 1.04TCr | 1.24TCr | 1.33TCr | 1.12TCr | |||||
Total Cash And Short Term Investments | 1.61TCr | 1.93TCr | 2.23TCr | 2.81TCr | 2.11TCr | |||||
Accounts Receivable, Total | 246.3Cr | 336.7Cr | 591Cr | 494.7Cr | 659Cr | |||||
Other Receivables | 25Cr | 3.1Cr | 14Cr | - | 10Cr | |||||
Total Receivables | 271.2Cr | 339.8Cr | 605.3Cr | 494.7Cr | 669.1Cr | |||||
Inventory | - | - | - | 5.7Cr | 6.2Cr | |||||
Total Current Assets | 1.88TCr | 2.27TCr | 2.84TCr | 3.31TCr | 2.79TCr | |||||
Gross Property Plant And Equipment | 100Cr | 134.3Cr | 181.7Cr | 231.7Cr | 272.8Cr | |||||
Accumulated Depreciation | -26Cr | -37Cr | -50Cr | -68Cr | -84Cr | |||||
Net Property Plant And Equipment | 74Cr | 98Cr | 132.2Cr | 164.1Cr | 189.1Cr | |||||
Long-term Investments | 108.1Cr | 37Cr | 13Cr | 13Cr | 23Cr | |||||
Goodwill | - | - | - | - | 253.5Cr | |||||
Other Intangibles, Total | 34Cr | 25Cr | 15Cr | 10Cr | 1.23TCr | |||||
Accounts Receivable Long-Term | 2Cr | 2.7Cr | 4.8Cr | 6.2Cr | 5.2Cr | |||||
Deferred Tax Assets Long-Term | 18Cr | 26Cr | 25Cr | 21Cr | 91Cr | |||||
Total Assets | 2.11TCr | 2.46TCr | 3.03TCr | 3.53TCr | 4.58TCr | |||||
Liabilities | ||||||||||
Accounts Payable, Total | - | 35Cr | - | - | - | |||||
Accrued Expenses, Total | - | 30Cr | - | - | - | |||||
Current Portion of Leases | 4.2Cr | 6.2Cr | 7.4Cr | 9Cr | 9.2Cr | |||||
Current Income Taxes Payable | - | - | - | 5.4Cr | 171Cr | |||||
Unearned Revenue Current, Total | 2.6Cr | 2.6Cr | 3.3Cr | 3.3Cr | 2.4Cr | |||||
Other Current Liabilities | 118.5Cr | 83Cr | 171.6Cr | 230.7Cr | 348.2Cr | |||||
Total Current Liabilities | 125.3Cr | 156.8Cr | 182.3Cr | 248.4Cr | 530.8Cr | |||||
Long-Term Leases | 28Cr | 36Cr | 52Cr | 68Cr | 94Cr | |||||
Unearned Revenue Non Current | 49Cr | 49Cr | 48Cr | 48Cr | 48Cr | |||||
Deferred Tax Liability Non Current | - | - | - | - | 235.9Cr | |||||
Other Non Current Liabilities | 50L | 1.3Cr | 1.1Cr | 3.5Cr | 3Cr | |||||
Total Liabilities | 202.2Cr | 243.1Cr | 283.7Cr | 367.9Cr | 911.4Cr | |||||
Common Stock, Total | 6.6Cr | 6.6Cr | 6.6Cr | 6.6Cr | 6.6Cr | |||||
Additional Paid In Capital | 1.19TCr | 1.2TCr | 1.23TCr | 1.25TCr | 1.26TCr | |||||
Retained Earnings | 710.7Cr | 1TCr | 1.5TCr | 1.9TCr | 2.36TCr | |||||
Comprehensive Income and Other | 5.4Cr | 8.1Cr | 9.8Cr | 6Cr | 49Cr | |||||
Total Common Equity | 1.91TCr | 2.22TCr | 2.74TCr | 3.16TCr | 3.67TCr | |||||
Total Equity | 1.91TCr | 2.22TCr | 2.74TCr | 3.16TCr | 3.67TCr | |||||
Total Liabilities And Equity | 2.11TCr | 2.46TCr | 3.03TCr | 3.53TCr | 4.58TCr | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 6.54Cr | 6.54Cr | 6.54Cr | 6.53Cr | 6.35Cr | |||||
ECS Total Common Shares Outstanding | 6.54Cr | 6.54Cr | 6.54Cr | 6.53Cr | 6.35Cr | |||||
Book Value / Share | 292.31 | 339.23 | 419.77 | 483.85 | 577.54 | |||||
Tangible Book Value | 1.88TCr | 2.19TCr | 2.73TCr | 3.15TCr | 2.18TCr | |||||
Tangible Book Value Per Share | 287.14 | 335.35 | 417.54 | 482.3 | 343.39 | |||||
Total Debt | 32Cr | 42Cr | 60Cr | 77Cr | 102.9Cr | |||||
Net Debt | -1.58TCr | -1.89TCr | -2.17TCr | -2.74TCr | -2.01TCr | |||||
Debt Equivalent Oper. Leases | 2.4Cr | 80L | - | - | - | |||||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||||
Inventories - Raw Materials, Total | - | - | - | 1.4Cr | 40L | |||||
Inventories - Finished Goods, Total | - | - | - | 5.9Cr | 7.9Cr | |||||
Machinery, Total | 42Cr | 54Cr | 65Cr | 91Cr | 99Cr | |||||
Full Time Employees | 781 | 1.21T | 1.66T | 2.2T | 2.68T |
- Stock Market
- Equities
- GMAB Stock
- Financials Genmab A/S
- Balance Sheet
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















